Medeva suffered a blow yesterday with the revelation that Johnson Matthey has been granted registration with the US Drug Enforcement Administration as a bulk manufacturer of its best-selling hyperactivity drug, methylphenidate. Medeva had been the only generic maker of the controlled drug, which raised sales 89 per cent to £66m last year. JM, best known as a precious metals refiner, must still gain approvals from the US Food and Drug Administration. Medeva, which is in talks with Fisons, saw its shares sink 4p to 228p.
Welcome to the new Independent website. We hope you enjoy it and we value your feedback. Please contact us here.
Blow for Medeva